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Abstract
It is difficult to describe host–
microbe interactions in a manner
that deals well with both patho-
gens and mutualists. Perhaps a way
can be found using an ecological
definition of tolerance, where tol-
erance is defined as the dose
response curve of health versus
parasite load. To plot tolerance,
individual infections are summa-
rized by reporting the maximum
parasite load and the minimum
health for a population of infected
individuals and the slope of the
resulting curve defines the toler-
ance of the population. We can
borrow this method of plotting
health versus microbe load in a
population and make it apply to
individuals; instead of plotting just
one point that summarizes an
infection in an individual, we can
plot the values at many time points
over the course of an infection for
one individual. This produces
curves that trace the course of an
infection through phase space
rather than over a more typical
timeline. These curves highlight
relationships like recovery and
point out bifurcations that are
difficult to visualize with standard
plotting techniques. Only nine ar-
chetypical curves are needed to
describe most pathogenic and mu-
tualistic host–microbe interactions.
The technique holds promise as
both a qualitative and quantitative
approach to dissect host–microbe
interactions of all kinds.
When I get infected, I don’t think, ‘‘my
TLRs and inflammasomes are activating!’’
As an infected patient, I worry about two
things: ‘‘how sick am I going to get?’’ and
‘‘whenamIgoingtogetbetter?’’Physicians
and nurses understand these questions
innately because it is their job to keep us
from getting sicker and to bring us back to
health. There is an unfortunate disconnect
between theseissuesandthe questionsbasic
scientistsstudy.Basicscientistsareterrificat
uncovering the fundamental mechanisms
controlling the activation of immune re-
sponses, identifying the effectors that clear
microbes, and determining how much
pathology will be caused by an infection.
However, it is difficult to move from these
molecular markers to the emergent prop-
erties of health and recovery in a patient.
Here I discuss two frameworks for
considering the questions ‘‘how sick will
I get?’’ and ‘‘when will I get better?’’
The first is the idea of tolerance–the dose
response curve of health with respect to
microbe number in a host population.
This concept is well established in the
plant literature [1–5] and has crossed over
recently to discussions about infections in
animals [6–8]. The second, and focus of
this perspective, is a discussion on how to
take this concept of a health-by-microbe
space as defined by tolerance curves in
populations and apply this to individuals.
This approach highlights parts of the
infectious process that are understudied
and provides a new quantitative approach
for attacking this problem.
There are many other models that
describe host–microbe interactions, rang-
ing from discrete mathematical models to
global theories, and they run the gamut
from mathematically rigorous construc-
tions to thought-provoking cartoons [6,9–
17]. Each model is useful for highlighting a
different aspect of host–microbe interac-
tions, but the purpose here is to discuss
tolerance and its extensions.
Summarizing Infections in
Populations Using the Concept
of Tolerance
How can we summarize an infection by
reducing it to a small number of points that
can be compared within an infected
population? One way is to pick obvious
landmarks from health or microbe timelines
of the infection, such as the peak parasit-
emia or the lowest health. If we plot these
values together on a health-by-microbe
graph we produce a single point for a
patient. By collecting many of these points
we can create a scatter plot showing what
happens when a population is exposed to
this pathogen. Ecological immunologists
have defined an elegant system for discuss-
ing such graphs in which the relationship
between health and microbe numbers in a
scatter plot is defined as tolerance [1,2–
8,18]. Tolerance is the dose response curve
for the system; it defines the slope of health
to parasite load in a population.
Theconceptoftolerancecan beused asa
tooltodissectinfections.Bymonitoringhow
the curve changes when host genetics or
environments are altered we can learn
about the factors contributing to a host–
microbe interaction. Tolerance allows us to
differentiate between physiological mecha-
nisms that are mostly required to clear
pathogens and distinguish these from mech-
anisms that impact our health. This second
group of mechanisms tends to be discussed
less than immune effectors. Tolerance
promises to teach us how to tune a body’s
response sothat we preventmicrobe growth
while limiting the negative effects on health.
Tolerance is useful for studying popula-
tions, not individuals. A tolerance curve
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certain manner to a given pathogen and we
can plan our treatment accordingly. If a
newly infected patient walks into a doctor’s
office there are two barriers to using
tolerance to treat that person as an
individual. The first barrier is that we
would have to let the patient reach peak
parasitemia and minimum health to place
them on the above tolerance curve, and by
that point they would have likely suffered
through the worst part of the infection; that
is no help. What we learn from a tolerance
curve depends upon the way we define it; if
we use the maximal parasite load and
minimal health to summarize infections,
then we don’t learn anything about recov-
ery. The second barrier is that even if we
could gather these summary data, we can
only place one point on the scatter plot for
this patient. This might tell us that the
patient is aberrant, if they fall far from the
curve, but we can’t measure their tolerance
because the patient represents one point on
the curve. We aren’t measuring their
response in a variety of states and therefore
can’t generate a dose response curve. How
canwe apply this idea of health-by-microbe
space to personalized medicine?
Applying Health-by-Microbe
Number Space to Individuals
The conventional method of following
infections is to plot dependent variables
(for example: parasitemia, fever, anemia,
weight loss) versus time; this obscures some
important relationships (Figure 1A). For
example, it is simple to pick out the peak
values and times for health and parasit-
emia, but the relationship between health
and parasitemia is harder to see because
the relationship changes continuously. We
presume that parasite load drives changes
in health, but we seldom monitor this
directly.
What would happen if instead of taking
the peak parasitemia and minimum health
as a summary of an infection, we plotted
health-by-microbe values at every time
point [11]? Imagine the individual depict-
ed in Figure 1A. This patient is initially
infected by a parasite, which produces a
single large red lump on his hand. The
parasite reproduces, creating more red
lumps, but this doesn’t have a large effect
on health. At some point the immune
response turns on and the parasites are
removed; the patient now suffers an
immunity-driven loss of health, as indicat-
ed by his posture. Ultimately, the patient
recovers his initial health and all of the
parasites are cleared. This is a resilient
system. By resilience, I mean the proper-
ties of a system that push it back to its
original state following a perturbation.
That we get better following an infection
means that we are resilient.
Instead of plotting parameters versus
time, I’ve plotted dependent parameters
against each other in the phase plane as
health-by-microbe number in Figure 1B.
This produces a looping curve that better
shows the relationship between health and
microbe number across the whole infec-
tion. This relationship changes across the
course of the infection: In the first portion,
microbe load increases without affecting
health. Next, both health and microbe
numbers simultaneously crash. Finally,
health increases and microbe numbers
drop to zero.
Though all of the information is present
in the original, this new type of plot reveals
some properties that are hard to visualize
from the timelines. It is clear that in this
infection, microbes are not the direct cause
of pathology; rather, the immune response
is causing damage because there is no
pathology until microbe clearance begins.
The relationship that becomes very ap-
parent out in this presentation is recovery;
at some point during the infection the
patient heals. Much of our research into
microbial pathogenesis is directed towards
limiting microbe growth or limiting pa-
thology with the hope that if we don’t get
severely ill then it will be easier to recover.
This graphing approach highlights recov-
ery and provides a quantitative method for
measuring recovery.
This presentation is useful as a two-
dimensional map and it is easy to overlook
the hidden third property–velocity. The
spacing of each data point indicates how
quickly an individual passes through
health-by-microbe space (Figure 2A). For
example, it is easy to imagine two
individuals that traverse the same health-
by-microbe space but differ in their
velocity and that it is the velocity that
leads to different outcomes. A change in
velocity (acceleration) during the course of
the infection in an individual also provides
useful information (Figure 2B). For exam-
ple, when the rate of parasite growth
decelerates, that suggests that antimicro-
bial effectors are being produced. Like-
wise, when health starts to accelerate in a
positive direction, this suggests that repair
mechanisms are being expressed. It is
therefore important to study the velocity
and acceleration of these curves in addi-
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Figure 1. Plotting data in the phase plane to better monitor infections. (A) A sick
‘‘patient’’ is depicted in frames at the top where the red dots indicate parasites and the stature of
the ‘‘patient’’ depicts health. In a simple timeline, parasites can be seen to rise and fall and the
health falls and returns to its original levels. The relationship between health and parasite levels is
visible but not as simple to interpret as shown below in (B). (B) The curves from (A) are replotted
in a health by parasite load phase plot. The plot shows three sections: First, the parasites grow but
do not affect health (dark blue). The slope here is quite flat. Second, (medium blue) the host
begins to clear the pathogens but the health crashes as well in this pathogenesis portion of the
plot. Third (light blue), the health recovers while the microbes continue to be cleared.
doi:10.1371/journal.pbio.1001158.g001
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The disease curve shown in Figure 1B is
drawn in two dimensions, but there is no
theoretical limit to the number of dimen-
sions that could be used. Physicians
working in an intensive care unit might
find this obvious as they monitor dozens of
parameters when they coax a person’s
health back to a survivable range. Those of
us studying microbial pathogenesis in the
lab tend not to look at all of these
parameters at once, but by drawing even
two-dimensional disease curves explicitly
we can highlight processes that have been
understudied.
Applying the Idea of Health-by-
Microbe Space Broadly to
Infections
Having generated a disease curve from
an imaginary infection, it is worthwhile to
think about how these curves might look
for well-studied infections. I suggest that
there is a relatively small alphabet of
curves that can describe most host–mi-
crobe interactions.
Regarding pathogens: In curve one
(Figure 3), which could be used to
describe an acute infection of uncompli-
cated dengue or flu, the pathogen levels
rise, health falls, and both ultimately
return to original healthy levels. Curve
two depicts a situation where the host
clears the pathogen but suffers irreversible
damage, as might occur in a case of
encephalitis or gangrene. Curve three
shows a case where the microbe is cleared
but the host becomes locked into an
inflammatory state that causes further
damage, triggering an autoimmune dis-
ease like reactive arthritis or rheumatic
fever. The fourth curve shows a stable
and non-resolving infection like tubercu-
losis (or see [19] for a related curve). The
health placement of this whorl will vary
with the particular infection; there are
some situations, as with herpes or vari-
cella infections where the steady state
health of the host would be normal (or
perhaps higher than the uninfected state
as discussed below). The fifth curve shows
the outcome of septicemic shock–like
illnesses where the body is not failing to
clear microbes, but the host dies because
of overwhelming pathology. The final
pathogenesis curve, six, depicts a situation
where the host can’t control the growth of
a microbe and this ultimately leads to
death, for example, an uncontrolled
gangrene or Streptococcus pyogenes infection.
These curves can also be used to
describe mutualistic host–microbe interac-
tions; this is critical because if new a
system that strives to explain host–microbe
interactions can’t describe mutualists as
readily as it describes pathogens, then it is
dead on arrival. Three of the disease
curves described above can be inverted or
rotated upwards to describe the interac-
tion of hosts with beneficial microbes.
There aren’t corresponding mutualist
curves for each disease curve, as not all
of the pathogenesis curves make sense
when flipped. For example, a pathogenic
infection that led to an unstable ever-
decreasing health would be inverted to
create a curve that led to constantly
increasing health. This is a formula to
create a superhero, which doesn’t happen
often enough in modern medicine. Curve
seven describes a fleeting interaction with
a mutualist, perhaps a probiotic; the
microbe provides benefit to the host while
it is on its limited journey through the
digestive track, and this benefit ends once
host and microbe part ways. Curve eight
describes a permanent change that could
be induced in a host by a live vaccine that
remains even after the attenuated patho-
gen has been removed. In this case it is
likely that the initial infection would cause
some pathology but would ultimately
result in higher health. That higher health
would be conditional, as it would depend
upon later exposure to the infected
pathogen. Curve nine describes a long-
term mutualistic interaction that reaches a
relatively steady state, like the association
of humans with their gut microbiota or
endosymbionts that can protect insects
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Figure 2. The contribution of velocity to disease curves. The cartoons in this article don’t show imaginary data points and thus don’t give an
impression of the velocity that a host will pass through health-by-microbe space. Here I’ve used vectors to show velocity. (A) Depicts two curves, one
resilient and another leading to parasite growth and host death. Near the origin, both curves traverse the same space and can’t be distinguished on
this basis; however, the curves differ in velocity. This highlights the point that it is important to measure velocity when plotting these curves. (B)
Depicts a bifurcation point in a curve after an unknown ‘‘something changes’’. The three following curves differ in their velocity as indicated by the
length and direction of the vector arrows. On the right, the vectors are compared next to triangles to make it easier to see the components
controlling parasite growth and health. The green curve has exactly the same health to parasite slope as the original, but the velocity of the curve is
reduced. Perhaps an antimicrobial has been induced that blocks parasite growth but does not harm the host. The blue curve has the same parasite
growth rate but the slope is steeper. In this case an ineffective and host-damaging immune response could have turned on. The red curve shows a
reduction in parasite growth and a decrease in slope. Here, an effective but host-damaging antimicrobial may have been produced. This figure
highlights the importance of measuring the acceleration of these curves.
doi:10.1371/journal.pbio.1001158.g002
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[20–24].
All of the curves described above were
drawn as strictly increasing or decreasing
health, but there are some examples that
could cross the line repeatedly. The bobtail
squid–Vibrio fischeri symbiosis provides an
example [25]. This squid has a light-
producing organ that relies upon the bacte-
rium V. fischeri to produce the light. These
bacteria are harvested from seawater by the
squid and are not passed down maternally.
Every morning, the squid squirts out the
majority of the bacteria in the light organ
and then the organ regenerates and the
bacteria grow back. This will produce a
looping health-by-microbe curve that cycles
every day. Herpes infections in mice, though
they cause short-term decreases in health,
can be protective against other infections
[26]. This sort of curve would resemble the
mutualist curve nine, except that it would
initially dip below 100% health before it hit
its final steady state.
There are cases where these sorts of phase
curves will not be helpful in dissecting an
infection. For example, if a parasite doesn’t
replicate in the host, a phase curve of
parasite number versus pathology will not
be informative. An example of such a
situation would be the pathology that
hookworms or ascaris cause when the
worms migrate through our bodies on the
way to our guts, as this pathology doesn’t
depend upon the replication of the parasites.
Defining Microbe Levels
It should be simple to determine
microbe levels for many pathogens. In-
sect-borne pathogens will be particularly
easy because these have to reach relatively
high levels in the circulation in order to be
taken up by a blood-feeding insect.
Plasmodia, trypanosomes, filarial worms,
and arboviruses fit into this class since
pathogen levels can be measured from the
blood. Diarrhea-causing infections that
shed microbes should be equally simple
to assess. Infections of immune cells, like
HIV, are also addressable in this fashion.
Theoretically, this approach will work
for all infectious diseases because there is a
relationship between the microbe and
host, but this isn’t going to be simple to
assess with pathogens that infect deep
tissues and don’t circulate. For example,
there aren’t simple methods of determin-
ing how many tuberculosis bacilli or
pneumonia-causing bacteria are found in
an infected lung of a living patient.
Likewise, it isn’t simple to determine the
amount of hepatitis C virus growing in a
liver. These are two simple problems, but
there will likely be situations where
microbes infect a variety of hard to assay
tissues and each tissue will contribute
differently to health. Our inability to
measure the levels of these pathogens does
not mean that these relationships do not
exist. We will make progress with systems
where it is immediately feasible to do
experiments. Success with these infections
will drive interest in applying this ap-
proach to more difficult situations.
I’ve described these curves as if parasites
are simply unchanging particles that need
to be counted; this is clearly an oversimpli-
fication and we will eventually need to deal
with the microbe’s varying contribution to
pathology [18]. Hosts and pathogens form
systems in which the behavior of each
component is so dependent upon the other
that we cannot easily separate them. Hosts
have tolerance curves and the properties of
infecting microbes describe a similar viru-
lence curve. We already know that microbe
behavior will change as they find them-
selves in extracellular or intracellular com-
partments or within different organs. Mi-
crobe behavior will also vary over time as
they switch from vegetative to transmissive
forms. Still, we can make progress imme-
diately by simplifying the system, and later
we can add the complications caused by
microbial participation.
How Can We Define ‘‘Health’’?
Phase plots like these require microbe
loads to be plotted against health, and
though it is reasonably clear what consti-
tutes microbe load, defining ‘‘health’’ is
more contentious. The answer, from an
evolutionary perspective, is that health is
the reproductive fitness of an individual.
But this isn’t an acceptable answer for
modern medicine, where the focus lies on
the quality of life and lifespan. In modern
medicine, health can be any physiological
correlate that matters to patients or
scientists. It would be useful to define a
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Figure 3. Nine simple curves describe the infectious route of all infections. Curve
definitions: Pathogenic: 1. Recovery (uncomplicated flu, measles, gastritis). 2. Permanent and stable
disability (lasting meningitis/encephalitis damage). 3. Unstable disability (rheumatic fever sequelae
orreactivearthritis). 4.Persistent pathogeninfection(tuberculosis,herpes).5.Deathwhiledefeating
a microbe (sepsis). 6. Uncontrolled microbial growth and death. Mutualistic: 7. Short-term
colonization with a beneficial microbe (transient probiotics). 8. An infection that is cleared but
permanently changes the state of the host (live vaccines). 9. Persistent infection with a mutualist
(Rhizobium, Hamiltonella, Wolbachia [20–24], herpes [26]).
doi:10.1371/journal.pbio.1001158.g003
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as it would enable us to compare between
diseases.
Some commonly used health parameters
won’t work for these plots; for example,
survivalisa terrifichealthindicatorbutisn’t
useful in a phase plot because it is binary–
the host is alive or dead.
To plot phase pictures like those
depicted in Figure 3, we need health
outputs with a broad dynamic range. It
is tempting to use cytokine or immune
effector levels as molecular markers, but
these don’t necessarily correlate with
disease. We know that there is a tolerance
curve that correlates health to microbe
load. Similarly, for every immune effector
or cytokine, there is a tolerance curve that
correlates microbe levels to the levels of
the effector, but unfortunately there is
another tolerance curve that correlates
effector level to health. The problem is
that we don’t always measure both of these
curves. It might be simpler to start with the
downstream symptoms that we care about.
Gross measurements such as weight,
hematocrit, organ function, energy stores,
appetite, tissue damage, fever, and activ-
ity–disease symptoms–could serve well.
Such measurements are often decried as
‘‘fuzzy’’ because we can’t trace directly
how these properties connected to the
immune response, but this is why these
responses are so interesting; that we see
individual variation in health in individu-
als suffering similar infections means that
there are processes linking health and
immunity that we still don’t understand.
The phase picture approach will let us
follow these changes and learn what is
necessary to help patients; the gross
physiological mechanisms that control
our daily health are altered by infection.
The idea of health space and disease
curves could be used prospectively to find
useful health correlates if none exist yet.
Imagine an infection where the typical
health correlates aren’t providing good
indicators of outcome. It might be possible
to generate health-by-microbe curves
while searching for biomarkers that move
in the manner expected for a resilient
infection. This approach could be used to
identify transcripts or cytokines or metab-
olites that correlate well with different
parts of the expected disease curve, be it
the health crash or recovery.
I am using a narrow definition of health;
in these plots, ‘‘health’’ measures the
current level of some interesting parame-
ter. If that level is normal, then the patient
is currently healthy. This could create
some confusion with other definitions for
health; for example, a patient infected with
a single virion of an always fatal virus will
appear healthy by these standards but will
soon die. Is that person really healthy?
This raises the distinction between health
as an immediate property and a predictive
property; are you healthy now and will
you be healthy tomorrow? These curves
are currently descriptive and report the
path that a patient took through the course
of an infection. As we gather a larger data
set, the curves will become predictive
because we will learn which spaces and
velocities suggest trouble. Hopefully we
will get to the point where we can look at
how health correlates change with respect
to each other and predict outcomes
without measuring pathogen load directly.
No matter how much data we gather,
there are some parts of the curves that
may never contain much predictive infor-
mation. The very start of infections could
be like this, where the microbe load is too
low to measure and health has not yet
been knocked out of the normal range.
Disease Curves Emphasize
What We Don’t Know
Perhaps the most important character-
istic of these disease curves is that they
highlight the parts of disease processes that
we have yet to explore. Resilience, the
ability to return to the starting state, is one
such property. The current focus of host–
microbe interactions is on the immune
response and subsequent pathogenesis. It
is simple to find textbooks concerning the
induction of the immune response, im-
mune effectors, or microbial virulence
factors. The way we run most experiments
makes us experts at describing exactly how
sick an individual will get during an
infection, but we tend not to measure
recovery. Our assumption is that if we can
limit the depth of an illness then we will
have a shallower hole to escape. We hope
to improve patient health by decreasing
the distance that a patient has to recover.
Does this work?
We know little about how an animal
recovers from an infection. Recovery must
be an active process. Damage has to be
repaired, energy tradeoffs have to be reset,
and physiological systems have to be
brought back to a standard healthy state.
Phase diagrams like those shown in
Figure 3 highlight this recovery part of
the curve; for example, in Figure 3, curves
2 and 3 (and possibly 4 and 5) show the
host is capable of clearing the infection but
faces a problem recovering. These curves
could provoke questions and new methods
for studying recovery. What is the slope of
health-by-microbe number in a recovery
curve and can this vary? Can recovery
occur only after the microbes are cleared
or can it start earlier? Do all health traits
recover with the same health by microbe
slope or health by time slope? Do all
pathogenic infection curves trace a clock-
wise path? These curves would be partic-
ularly useful for dissecting processes
thought to be involved in the resolution
of inflammation or tissue repair.
There are some problems that could
particularly benefit from analysis in the
phase plane, for example, aging-induced
immune senescence and frailty. We know
that the immune system changes as we age,
but how exactly does this lead to failure?
Are disease curves more likely to bifurcate
from the normal curves in the aged? If this
is the case then we can learn much by
determining where the curves are bifurcat-
ing. Figure 4 depicts a resilient curve in
black and four different bifurcating curves
in red. Curve one and other curves like it
that would peel off in the dark blue zone
would likely have defects in clearing
pathogens. Curve two could have defects
in both pathogen clearance and damage
control. Curves three and four, which peel
off in the light blue zone, likely have defects
in repair but seem to be able to clear
pathogensproperly.Does anelderly patient
trace the same health space as a young
patient but at a different velocity, or is the
curve warped? By observing changes in the
shape and speed of these curves we could
perhaps diagnose the effects of age on
immunity better than by studying individ-
ual components of the immune response.
What Do We Need to Do to
Make Disease Curves Useful?
If we understood the normal traces of
infections, these curves could be immedi-
ately helpful to patients in two ways. First,
we might be able to define ‘‘bad neigh-
borhoods’’ in the health-by-microbe land-
scape. These would be regions in which
nobody fares well, and when a patient is
identified in this region they could be
targeted for special attention. With bad
neighborhoods, a single sample measuring
health and microbe levels would let the
physician know whether the patient was at
risk. Second, if we could plot a fragment of
a patient’s infection curve, we could
determine their likely disease trajectory.
If the patient has a favorable trajectory
they might not need significant support,
whereas a patient with a similar general
health and microbe load might require
immediate assistance. There are situations
where it is expected that health will drop,
but this could be acceptable so long as the
PLoS Biology | www.plosbiology.org 5 September 2011 | Volume 9 | Issue 9 | e1001158microbes are being cleared at an appro-
priate rate.
To collect examples of these processes
we will have to pick our infections
carefully and start with model systems.
As discussed above, we should concentrate
first on infections where it is easy to
quantify the pathogen. However, patho-
gens that don’t circulate at high levels
could be followed using luminescent or
fluorescent microbes in model systems by
measuring antigen levels in patients or by
measuring pathology that was indicative of
pathogen load. These experiments obvi-
ously have to be done in model organisms
that can be infected and repeatedly
monitored. If we use small model organ-
isms like flies, worms, and fish that can be
ground up and tested for pathogen loads,
we can gather large amounts of data. This
would remove the personalized disease
curve aspect of the process, but if the
curves were reproducible and the animals
genetically similar this process would still
yield the desired information.
Recently there have been arguments
made that more work must be done on
humans because mechanistic immunolog-
ical models are not translating well from
models into the clinic [27]. One common
explanation for this perceived problem is
that model organisms are too diverged to
teach us about people. A second possibil-
ity, highlighted by our lack of understand-
ing of the forces shaping disease curves, is
that we have been systematically asking
the wrong questions, and we’ve been
doing that in at least two different ways:
First, we’ve been looking at the immune
response without measuring microbes at
the same level of resolution (if we measure
them at all). The immune response pushes
against microbes, and it is impossible to
understand the activity of the immune
response without knowing what the mi-
crobes are doing. Second, we have been
looking at proximal immune responses
without measuring real health outputs.
The precise mechanism of immune acti-
vation does not define how sick an animal
will get or whether it will be able to
recover. We need to connect molecular
mechanism with outcome and that has yet
to be achieved in any system.
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Figure 4. Bifurcation points teach us about defects in the immune response. A resilient
disease curve is shown in black and four bifurcating disease curves are shown in red. The first
bifurcating curve leads to increased death because of a failure to clear microbes. The second
bifurcating curve could have a problem both clearing microbes and preventing pathogenesis.
The third and fourth bifurcating curves have defects in recovery but are capable of clearing
pathogens. Each bifurcating curve or pair of curves defines regions of disease space that suggest
different defects in the immune response.
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